(1 - 13 from 13
)
Oncology Data Advisor - Moxetumomab Pasudotox-Tdfk for ...
oncdata.com
· Robert Kreitman, MD. Hairy cell leukemia (HCL) comprises only 2% of all leukemias and has limited treatment options. In a phase 3 trial, a team of researchers led by Robert Kreitman, MD, a medical oncologist at the National Cancer Institute, found that moxetumomab pasudotox-tdfk, a recombinant CD22-directed cytotoxin, achieved a high rate of durable response
AZ nabs US approval for new leukaemia drug Lumoxiti - PMLiVE
www.pmlive.com
... to ten years after their first treatment,” said Robert Kreitman of the National Cancer Institute (NCI) in the US, the lead investigator in the study.
AstraZeneca wins FDA OK for leukemia drug | BioPharma Dive
www.biopharmadive.com
... their first treatment," said Robert Kreitman, head of clinical immunotherapy section, Center for Cancer Research, National Cancer Institute, ...
sorted by relevance / date